Promising Results for GLP-1 Receptor Agonists in Reducing Chronic Migraine Frequency
A pilot study reveals that GLP-1 receptor agonists, such as liraglutide, may significantly reduce the frequency of chronic migraines, offering new hope for treatment-resistant patients.
Migraines affect approximately 15% of people worldwide, often leading to significant discomfort and disruption in daily life. While multiple treatments are available, some individuals do not find relief, or they experience adverse side effects that limit their options. Recent research introduces a novel approach using medications known as GLP-1 receptor agonists—drugs typically used for weight loss and diabetes management—as potential migraine therapeutics.
A pilot study conducted by Italian researcher Simone Braca and colleagues explored the effects of liraglutide, a GLP-1 receptor agonist, on individuals suffering from chronic migraines coupled with obesity. Over a 12-week period, 31 participants (mostly female) received liraglutide and documented their headache frequency. The findings revealed a substantial decrease in migraine days—reducing from an average of about 20 days per month to 11 days after treatment.
Approximately half of the participants experienced a 50% reduction in migraine frequency, with some showing even higher improvements—seven individuals saw up to a 75% decrease, and one participant became migraine-free. Mild gastrointestinal side effects such as nausea and constipation were reported but resolved without impacting the study.
Interestingly, the study indicated that weight loss was not the primary factor behind the migraine relief, as participants’ BMI remained largely unchanged. The researchers hypothesize that liraglutide may influence intracranial pressure (ICP), a known factor in migraine severity, although direct measurements were not taken in the study. Future research aims to clarify the mechanism at play.
This pioneering research opens new avenues for treating chronic migraines, especially in cases resistant to traditional therapies. While more extensive studies are necessary, these early results suggest that GLP-1 receptor agonists like liraglutide could become valuable tools in managing this debilitating condition.
source: https://medicalxpress.com/news/2025-07-ozempic-drug-significantly-frequency-chronic.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Ebola Vaccine Deployment at Congo Outbreak Epicenter Amid Containment Challenges
Urgent vaccination efforts are underway in Congo’s Kasai province to control the first Ebola outbreak in 18 years, amid logistical challenges and limited resources.
Innovative Protein 'Barcodes' Revolutionize Large-Scale Brain Circuit Mapping
A revolutionary genetic and computational approach using protein 'barcodes' enables highly accurate and cost-effective mapping of neural circuits in mammalian brains, promising to accelerate neuroscience research and brain disorder understanding.
Studies Reveal Connection Between Birth Difficulties and Adult Health Challenges
Research highlights the link between distressed births and increased risk of chronic and mental health issues in adulthood, emphasizing the importance of maternal care and early interventions.
Global Study Shows Increased Longevity for People with Dementia
A groundbreaking global study reveals that people diagnosed with dementia are living longer than before, thanks to advancements in diagnosis and care strategies. The research highlights regional differences and emphasizes the importance of ongoing efforts to improve life expectancy for dementia patients.